



1047 Elwell Court, Palo Alto  
CA 94303 USA  
Tel (US): +1 (650) 390 9000  
Tel (AU): 1-800-778-662  
Fax: +1 650 390 9007  
[www.airxpanders.com](http://www.airxpanders.com)

09 April, 2018

## **AirXpanders Announces Management Changes**

**Palo Alto, CA, United States – AirXpanders, Inc. (ASX: AXP)** announced today that Mr. Scott Dodson has resigned from the Company with Scott Murcay, the Company's current CFO/COO appointed Interim President & Chief Executive Officer. The final terms of Mr. Murcay's interim compensation will be announced when finalized.

Barry Cheskin, Co-Founder and Chairman of the Board said, "The Board believes that bringing on a new CEO at this time will help drive the business in this next phase, including refining and improving the effectiveness of our sales model while achieving operating cost efficiencies to reduce our quarterly cash burn and provide a clearer path to profitability. Our early experience in the U.S. gives us a high degree of confidence in the strength of AeroForm and the long-term outlook for the business."

"We appreciate Scott Dodson's efforts in leading AirXpanders through the early clinical trials in Australia and the U.S., the Initial Public Offering, FDA clearance and the launch of AeroForm in Australia and the U.S."

The Company has engaged Korn Ferry, a leading executive search firm, to assist it with identifying and hiring a new CEO. With the availability of strong talent in the medical device industry combined with the attractiveness of this opportunity, the Company believes it will be successful in appointing a new CEO in the near-term and will provide further updates regarding this on its first quarter results conference call.

In addition, AirXpanders has formed an Operating Advisory Committee of the Board to assist during a transition period consisting of the Chairman, Barry Cheskin, as well as Greg Lichtwardt and Dennis Condon, all current members of the Board. Each has substantial expertise in sales, marketing and executive management in the medical device and/or plastic surgery sector. The Operating Advisory Committee will help guide the management team to accelerate operational progress.

The Company expects to announce its first quarter results and Appendix 4C on April 27, 2018, noting that, while the financial reports have not yet been finalized, worldwide sales were basically flat compared to the fourth quarter of 2017, with U.S. sales up marginally. The Company had a cash balance at the end of the quarter of approximately US\$13.6 million which the Company believes is sufficient to fund its operations through 2018. The Interim President & CEO along with the Chairman plan to host the first quarter results call and intend to provide a further update on operational and leadership progress at that time.

- ENDS -

<b>Company</b>	<b>Investor relations</b>
Scott Murcray Interim President & CEO Tel: +1 (408) 242-8574 Email: <a href="mailto:smurcray@airxpanders.com">smurcray@airxpanders.com</a>	Rebecca Wilson WE Buchan Tel: +61 (3) 9866 4722 / + 61 (0)4417382391 Email: <a href="mailto:rwilson@we-buchan.com">rwilson@we-buchan.com</a>

### **About AirXpanders**

Founded in 2005, AirXpanders, Inc. ([www.airxpanders.com](http://www.airxpanders.com)) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company's AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA *de novo* marketing authorization in 2016, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, any preliminary financial results, forecasts relating to future costs, cash sufficiency forecast, the specific timing of successfully hiring a new CEO and the long-term prospects for the business, including the ability to improve the effectiveness of our sales model, achieve operating cost efficiencies, reduce cash burn and achieve profitability.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on February 28, 2018, including under the caption "Risk Factors," as well as other periodic reports filed with the SEC from time to time. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.

For more information, refer to the Company's website at [www.airxpanders.com](http://www.airxpanders.com).